Literature DB >> 9797238

Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.

C Solas1, Y F Li, M Y Xie, J P Sommadossi, X J Zhou.   

Abstract

An analytical methodology was developed to quantitate the intracellular nucleotides including mono-, di-, and triphosphates and the diphosphocholine derivative of (-)-2', 3'-deoxy-3'-thiacytidine (3TC) in human peripheral blood mononuclear cells (PBMCs). The procedure includes the resolution of 3TC nucleotides by solid-phase extraction (SPE) on an anion-exchange cartridge, with subsequent enzyme digestion of the resulting phosphates to the parent drug that is ultimately quantitated by high-performance liquid chromatography with UV detection (HPLC-UV). Validation was performed with PBMCs from healthy donors exposed to [3H]3TC, leading to the formation of intracellular nucleotides that were quantitated by anion-exchange HPLC with radioactive detection (HPLC-RA). These nucleotide levels served as reference values and were used for cross-validation with data obtained by HPLC-UV. An excellent correlation was established between the results obtained by HPLC-RA and those obtained by HPLC-UV, with a slope of the regression lines close to unity and intercepts near nullity as well as a correlation coefficient close to unity for all 3TC phosphates. The assay was characterized by a limit of quantitation below 1 ng (amount on column) with a precision (percentage of coefficient of variation of repeated measurement) ranging from 0.8 to 18.1% and an accuracy (deviation of the amount determined by HPLC-UV from the nominal reference value) varying from -14.8 to 19.4%. This methodology was successfully applied to determine the quantity of 3TC nucleotides in PBMCs of a patient infected with human immunodeficiency virus after oral administration of 3TC and stavudine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797238      PMCID: PMC105978     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Rapid quantitation of (-)-2'-deoxy-3'-thiacytidine in human serum by high-performance liquid chromatography with ultraviolet detection.

Authors:  X J Zhou; J P Sommadossi
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-04-11

2.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

3.  Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells.

Authors:  Y Törnevik; B Ullman; J Balzarini; B Wahren; S Eriksson
Journal:  Biochem Pharmacol       Date:  1995-03-15       Impact factor: 5.858

4.  Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells.

Authors:  J P Sommadossi; R F Schinazi; C K Chu; M Y Xie
Journal:  Biochem Pharmacol       Date:  1992-11-17       Impact factor: 5.858

5.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

Authors:  W Y Gao; T Shirasaka; D G Johns; S Broder; H Mitsuya
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Inhibition of mammalian DNA polymerase-associated 3' to 5' exonuclease activity by 5'-monophosphates of 3'-azido-3'-deoxythymidine and 3'-amino-3'-deoxythymidine.

Authors:  E G Bridges; A Faraj; J P Sommadossi
Journal:  Biochem Pharmacol       Date:  1993-04-22       Impact factor: 5.858

7.  Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells.

Authors:  B L Robbins; J Rodman; C McDonald; R V Srinivas; P M Flynn; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

Review 8.  Nucleoside analogs: similarities and differences.

Authors:  J P Sommadossi
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079

9.  High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.

Authors:  D Havlir; S H Cheeseman; M McLaughlin; R Murphy; A Erice; S A Spector; T C Greenough; J L Sullivan; D Hall; M Myers
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

10.  Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells.

Authors:  L Cui; S Yoon; R F Schinazi; J P Sommadossi
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  11 in total

1.  Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Giuseppe Gumina; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

2.  Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.

Authors:  Zexun Zhou; John H Rodman; Patricia M Flynn; Brian L Robbins; Carrie K Wilcox; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry.

Authors:  E Font; O Rosario; J Santana; H García; J P Sommadossi; J F Rodriguez
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.

Authors:  J D Moore; G Valette; A Darque; X J Zhou; J P Sommadossi
Journal:  J Am Soc Mass Spectrom       Date:  2000-12       Impact factor: 3.109

5.  Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.

Authors:  A Darque; G Valette; F Rousseau; L H Wang; J P Sommadossi; X J Zhou
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 6.  Role of nucleoside diphosphate kinase in the activation of anti-HIV nucleoside analogs.

Authors:  B Schneider; R Sarfati; D Deville-Bonne; M Véron
Journal:  J Bioenerg Biomembr       Date:  2000-06       Impact factor: 2.945

7.  Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.

Authors:  J F Rodriguez; J L Rodriguez; J Santana; H García; O Rosario
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine.

Authors:  Huachun Chen; S Balakrishna Pai; Selwyn J Hurwitz; Chung K Chu; Yuliya Glazkova; Harold M McClure; Mark Feitelson; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

9.  Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.

Authors:  Yudong Quan; Bluma G Brenner; Maureen Oliveira; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Can urine lamivudine be used to monitor antiretroviral treatment adherence?

Authors:  Agibothu K Hemanth Kumar; Geetha Ramachandran; Periyaiyah Kumar; Vasanthapuram Kumaraswami; Soumya Swaminathan
Journal:  MedGenMed       Date:  2006-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.